CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
当前联合布鲁顿酪氨酸激酶抑制剂与免疫检查点抑制剂的 CAR-T 细胞策略
英文原题：Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors.
查看英文原题
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向CD19的嵌合抗原受体（CAR）T细胞疗法已在非霍奇金淋巴瘤、急性淋巴细胞白血病等难治性B细胞恶性肿瘤患者中显示出较高疗效。尽管结果令人鼓舞，多数患者的缓解仍不持久。此外，接受CD19 CAR-T 细胞治疗的患者可能发生严重甚至危及生命的不良事件，包括细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。目前正在研究多种联合治疗方案，以改善CAR-T 细胞在体内的功能和抗肿瘤作用，并减轻毒性。本综述讨论在B细胞淋巴系统恶性肿瘤患者中，将伊布替尼及免疫检查点抑制剂与CAR-T 细胞疗法联合应用的研究进展。
展开英文摘要原文
CD19-targeted chimeric antigen receptor (CAR) T cell therapy has shown high efficacy in patients with refractory B-cell malignancies such as non-Hodgkin lymphoma and acute lymphoblastic leukemia. Despite promising results, responses are not durable in most patients.
In addition, patients receiving CD19 CAR T cell therapy are at risk of developing severe, potentially life-threatening, adverse events including cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome. Many combinatorial approaches are currently being investigated to improve CAR T cell in vivo function, antitumor effects, and mitigate toxicities. In this review, we discuss the use of ibrutinib and immune checkpoint inhibitors in combination with CAR T cell therapy in patients with lymphoid B-cell malignancies.
论文信息
- 作者
- Mohty R、Gauthier J
- 第一作者单位
- Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
- 通讯作者单位
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. jgauthier@fredhutch.org.United States
- 文献类型
- 综述
- 期刊
- Bone marrow transplantation2021 Nov
- 原文标识
- PubMed 34290380 · DOI 10.1038/s41409-021-01420-9